Clinical Trials
3 trialsNCT04487106 2025-04-22
Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01907815 2018-04-06
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00920140 2014-04-02
Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
GlaxoSmithKline
Phase 2 Completed